Volume 11, Number 6—June 2005
Research
Integrating Escherichia coli Antimicrobial Susceptibility Data from Multiple Surveillance Programs
Table 1
Countries participating in the MYSTIC and SENTRY programs*
| System | North America | Latin America | Northern Europe | Southern Europe + South Africa | Western Pacific |
|---|---|---|---|---|---|
| MYSTIC (24 countries) | Canada (14, 97), United States (18, 816) | Argentina (3, 41), Brazil (3, 75), Colombia (1, 20), Mexico (4, 170) | Belgium (9, 572), Czech Republic (1, 90), Germany (7, 668), Poland (1, 70), Russia (1, 7),† Sweden (3, 153),† Switzerland (1, 40),† United Kingdom (8, 294) | Bulgaria (1, 10),† Greece (2, 37), Israel (1, 96), Italy (5, 369), Malta (1, 11),† Spain (5, 517), Turkey (9, 529) | Australia (1, 46), Hong Kong (1, 20),† Thailand (1, 70)† |
| Total (101 sites, 4,818 isolates) | 32 sites, 913 isolates | 11 sites, 306 isolates | 31 sites, 1,894 isolates | 24 sites, 1,569 isolates | 3 sites, 136 isolates |
| SENTRY (34 countries) | Canada (8, 1,334), United States (36, 5,438) | Argentina (2, 282), Brazil (5, 488), Chile (2, 610), Colombia (1, 181), Mexico (3, 166),† Uruguay (1, 17),† Venezuela (1, 72) | Austria (1, 105),† Belgium (1, 171), Germany (6, 440), Ireland (1, 52), Netherlands (1, 107),† Poland (1, 141), Russia (1, 6),† Sweden (1, 112), Switzerland (1, 380), United Kingdom (1, 260) | France (9, 1,086), Greece (1, 212), Israel (1, 128), Italy (4, 431), Portugal (1, 91),† South Africa (1, 76), Spain (3, 1,007), Turkey (3, 217) | Australia (4, 480), China (3, 62),† Hong Kong (1, 228), Japan (3, 93), Philippines (1, 130), Singapore (2, 118), Taiwan (3, 98) |
| Total (114 sites, 14,819 isolates) | 44 sites, 6,772 isolates | 15 sites, 1,816 isolates | 15 sites, 1,774 isolates | 23 sites, 3,248 isolates | 17 sites, 1,209 isolates |
*The number of participating centers at any point from 1997 to 2001 and number of isolates by country are indicated in parentheses.
†Countries excluded from analyses for insufficient data, as defined in the text.


